^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Ocular Melanoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Excerpt:
    TAFINLAR is indicated, in combination with trametinib, for...the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Front Oncol
    Title:

    Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

    Excerpt:
    Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.
    DOI:
    10.3389/fonc.2019.00232